Related Experiment Videos
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
Vikram Deshpande1, Afamefuna Nduaguba, Stephanie M Zimmerman
1Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, Massachusetts 02114, USA.
BMC Cancer
|February 10, 2011
Summary
Genomic analysis of biliary tract cancers (BTC) revealed PIK3CA mutations exclusively in gallbladder cancer (GBC), suggesting potential targeted therapy applications. KRAS mutations were found in other BTC subtypes.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Biliary tract cancers (BTC) exhibit heterogeneous genetics that require further definition.
- BTC includes intra- and extra-hepatic cholangiocarcinomas and gallbladder carcinomas.
Purpose of the Study:
- To characterize mutations in known oncogenes and tumor suppressor genes in BTC.
- To investigate the genetic landscape of advanced biliary tract cancers.
Main Methods:
- Utilized a mass spectrometry-based platform to analyze mutations.
- Tested a panel of 77 formalin-fixed, paraffin-embedded (FFPE) archived BTC cases.
- Interrogated common cancer-associated mutations in oncogenes and tumor suppressor genes.
Main Results:
- Confirmed mutations in KRAS, NRAS, and PIK3CA across the BTC cohort.
- Identified activating PIK3CA mutations exclusively in gallbladder cancer (GBC) (12.5%).
- Found KRAS mutations in intra-hepatic (13%) and perihillar cholangiocarcinomas (33%), but not in GBC or extra-hepatic cholangiocarcinoma.
Conclusions:
- Activating PIK3CA mutations are specific to GBC, indicating diagnostic and therapeutic implications.
- PIK3CA mutations in GBC may guide the use of PI3 kinase inhibitors.
- Genetic profiling of BTC subtypes can inform personalized treatment strategies.